Hematopoietic stem cell transplantation for sickle cell disease: Progress and challenges

Area of Science:

• Hematology
• Transplantation Medicine
• Genetic Blood Disorders

Background:

• Sickle cell disease (SCD) is a debilitating inherited blood disorder causing progressive organ damage.
• Hematopoietic stem cell transplantation (HSCT) is a potential curative therapy for severe SCD.
• Challenges to HSCT include donor availability and risks associated with the procedure.

Purpose of the Study:

• To review the balance between HSCT risks and benefits for patients with severe SCD.
• To identify knowledge gaps in HSCT for SCD management.
• To emphasize the importance of shared decision-making in SCD treatment.

Main Methods:

• Literature review of HSCT in sickle cell disease.
• Analysis of risks (toxicity, graft-versus-host disease, mortality) versus benefits (cure, organ damage mitigation).
• Discussion of patient and family perspectives on treatment decisions.

Main Results:

• Severe SCD necessitates balancing HSCT's curative potential against significant procedural risks.
• Graft-versus-host disease and preparative regimen toxicity are key complications.
• Information exchange is vital for informed patient-provider decision-making.

Conclusions:

• HSCT offers a pathway to cure for severe SCD, but careful risk-benefit assessment is essential.
• Further research is needed to optimize HSCT protocols and mitigate complications.
• Joint decision-making empowers SCD families to navigate complex treatment choices.